Disease Information
General Information of the Disease (ID: DIS00117)
| Name |
Corneal ulcer
|
|---|---|
| ICD |
ICD-11: 9A76
|
| Resistance Map |
Type(s) of Resistant Mechanism of This Disease
Drug Resistance Data Categorized by Drug
Approved Drug(s)
3 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
| Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Gentamicin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
| Pseudomonas aeruginosa ATCC 27853 | 287 | |||
| Pseudomonas aeruginosa isolates | 287 | |||
| Staphylococcus aureus ATCC 25923 | 1280 | |||
| Experiment for Molecule Alteration |
Whole genome sequence assay | |||
| Experiment for Drug Resistance |
Agar dilution method assay | |||
| Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
| Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Netilmicin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
| Pseudomonas aeruginosa ATCC 27853 | 287 | |||
| Pseudomonas aeruginosa isolates | 287 | |||
| Staphylococcus aureus ATCC 25923 | 1280 | |||
| Experiment for Molecule Alteration |
Whole genome sequence assay | |||
| Experiment for Drug Resistance |
Agar dilution method assay | |||
| Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
| Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Tobramycin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
| Pseudomonas aeruginosa ATCC 27853 | 287 | |||
| Pseudomonas aeruginosa isolates | 287 | |||
| Staphylococcus aureus ATCC 25923 | 1280 | |||
| Experiment for Molecule Alteration |
Whole genome sequence assay | |||
| Experiment for Drug Resistance |
Agar dilution method assay | |||
| Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
